Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Positron Emission Tomography/Computed Tomography (PET/CT) imaging using 18F-FDG is an important, commonly used cancer, neuroscience and cardio-vascular imaging methodology to detect disease and to monitor therapeutic interventions. While considerable technological progress of PET/CT systems has occurred over the last decade, we have not re-evaluated the ability to potentially reduce the radiation burden of the used PET imaging pharmaceutical (FDG).
This early phase trial intends to accomplish the following:
- to validate that the radiation dose burden from the PET imaging pharmaceutical (FDG) can be reduced by more than 50% from the current standard of clinical care (SOC) level without affecting the diagnostic ability;
- to confirm that a low dose approach will be feasible for response assessment;
- to validate that the difference in FDG uptake between imaging 60 min +/- 10 min post injection and 75 min +/- 10 min post injection is independent/equivalent of the injected FDG dose
- to validate a simulation methodology to streamline future dose finding studies for PET imaging pharmaceuticals.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43221
- The Ohio State University Wexner Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female patients greater than or equal to 18 years of age
- Patients scheduled for a standard of care PET/CT scan
- For female patients of child-bearing potential, the OSUWMC requirements for receiving the standard of care PET imaging agent and CT examination needs to be met
Exclusion Criteria:
- Participants who are pregnant or lactating
- Prisoners
- Participants incapable of giving informed consent
- Patients unable to lie flat on the scanner for extended periods of time
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Sub-Study A
Patients receive PET/CT scan on Gemini Astonish PET/CT
|
13 mCi 18F-FDG dose
5 mCi 18F-FDG dose
|
|
Experimental: Sub-Study B
Patients receive PET/CT scan on Biograph mCT
|
13 mCi 18F-FDG dose
5 mCi 18F-FDG dose
|
|
Experimental: Sub-Study C
Patients receive PET/CT scan on Discovery PET/CT
|
13 mCi 18F-FDG dose
5 mCi 18F-FDG dose
|
|
Experimental: Sub-Study D
Patients receive PET/CT scan on Vereos 128 digital PET/CT
|
13 mCi 18F-FDG dose
5 mCi 18F-FDG dose
|
|
Experimental: Sub-Study E
Patients receive lower radiation dose on Vereos 128 digital PET/CT
|
2.5 mCi 18F-FDG dose
6.5 mCi 18F-FDG dose
|
|
Experimental: Sub-Study F
Patients receive PET/SCAN using system that did not show equivalence in Sub-Study A-C
|
13 mCi 18F-FDG dose
We plan for the possibility that one of the three-Sub-Studies (A-B) would not demonstrate equivalency, and we would then perform a modified protocol in which the SOC dosing is compared to a lower and higher dose than originally tested.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Image quality
Time Frame: through study completion, on average 2-5 years
|
assessed by blinded readers
|
through study completion, on average 2-5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Artifacts
Time Frame: through study completion, on average 2-5 years
|
assessed by blinded readers
|
through study completion, on average 2-5 years
|
|
Lesion detectability
Time Frame: through study completion, on average 2-5 years
|
assessed by blinded readers
|
through study completion, on average 2-5 years
|
|
Image noise
Time Frame: through study completion, on average 2-5 years
|
assessed by blinded readers
|
through study completion, on average 2-5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Michael V Knopp, MD, PhD, Ohio State University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- RP0308/2014H0437
- R01CA195513 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.